Repertoire Immune Medicines Receives Funding From COVID-19 High Performance Computing Consortium
Round Type
Funding Round
CambridgeBiotechnologyHealth CareTherapeuticsDescription
Repertoire Immune Medicines, a clinical-stage biotech company tooled to decode and deploy the immune system across multiple major diseases, today announced that it has received funding from the COVID-19 High Performance Computing (HPC) Consortium, a private-public sector effort offering computing capabilities to support COVID-19 research programs. Repertoire’s research project aims to identify viral epitopes most likely to induce durable immunity to SARS-CoV-2, the virus that causes COVID-19, through induction of long-term memory in T cells. Under this grant, Repertoire will leverage the cloud computing resources of Amazon Web Service (AWS) to simulate and predict the complex immunological interactions across patient populations that lead to clearance of SARS-CoV-2.
Quick answer
Repertoire Immune Medicines raised an undisclosed amount in a Funding Round round, dated June 24, 2020. Repertoire Immune Medicines is based in Cambridge, Massachusetts, United States.
- How much did Repertoire Immune Medicines raise?
- Repertoire Immune Medicines raised an undisclosed amount in a Funding Round round on June 24, 2020.
- What does Repertoire Immune Medicines do?
- Repertoire Immune Medicines is a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines.
- Where is Repertoire Immune Medicines based and how big is it?
- Repertoire Immune Medicines is based in Cambridge, Massachusetts, United States. Fundz records about 83 employees.
- Who are the decision-makers at Repertoire Immune Medicines?
- Fundz holds 1 contact at Repertoire Immune Medicines. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Repertoire Immune Medicines that raised within 45 days of this round, from Fundz verified event records.
- Biohaven raised $450M (Funding Round) on August 7, 2020.
- ADARx Pharmaceuticals, Inc. raised $5M on August 7, 2020.
- Oncotelic Therapeutics raised $2M (Seed) on August 4, 2020.
- Kinnate Biopharma raised $88M on August 4, 2020.
- GENOCEA BIOSCIENCES, INC. raised $76M on August 3, 2020.
- MBX Biosciences, Inc. raised $34M (Series A) on July 27, 2020.
Who to call at Repertoire Immune Medicines, and when
A new round usually means Repertoire Immune Medicines is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Repertoire Immune Medicines raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Repertoire Immune Medicines, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Repertoire Immune Medicines. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Repertoire Immune Medicines raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Repertoire Immune Medicines raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.